

AWARD NUMBER: W81XWH-13-1-0288

TITLE: Microenvironment-Sensitive Multimodal Contrast Agent for Prostate Cancer Diagnosis

PRINCIPAL INVESTIGATOR: Allan E. David

CONTRACTING ORGANIZATION: Auburn University  
Auburn, AL 36849-0001

REPORT DATE: October 2015

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2015		2. REPORT TYPE Annual		3. DATES COVERED 9 Sep 2014 - 8 Sep 2015	
4. TITLE AND SUBTITLE Microenvironment-Sensitive Multimodal Contrast Agent for Prostate Cancer Diagnosis				5a. CONTRACT NUMBER W81XWH-13-1-0288	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Allan E. David  E-Mail: aedavid@auburn.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Auburn University 107 Samford Hall Auburn AL 36849-0001				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The goal of this work is to develop the materials and methods to non-invasively monitor the aggressiveness of prostate cancer. Prostate cancer is the second leading cause of death among men in the United States, yet no reliable diagnostic tools or effective therapies are currently available. There is increased focus on the development of tools for improved detection and monitoring of prostate cancer. In this work, we have developed magnetic nanoparticles that are able to detect and bind to PC3 prostate cancer cells. Using the particles' magnetic properties, they can be localized in the body using MRI. The addition of a fluorescent marker on the nanoparticle that is sensitive to proteolytic activity then provides a means to detect and quantify the aggressiveness of the cancer.					
15. SUBJECT TERMS Prostate cancer, nanomedicine, diagnosis, cancer staging, proteolytic activity; non-invasive detection; MRI					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT  Unclassified	18. NUMBER OF PAGES  40	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT  Unclassified	b. ABSTRACT  Unclassified	c. THIS PAGE  Unclassified			19b. TELEPHONE NUMBER (include area code)

## Table of Contents

	<u>Page</u>
<b>1. Introduction.....</b>	<b>4</b>
<b>2. Keywords.....</b>	<b>4</b>
<b>3. Accomplishments.....</b>	<b>4</b>
<b>4. Impact.....</b>	<b>16</b>
<b>5. Changes/Problems.....</b>	<b>17</b>
<b>6. Products.....</b>	<b>18</b>
<b>7. Participants &amp; Other Collaborating Organizations.....</b>	<b>19</b>
<b>8. Special Reporting Requirements.....</b>	<b>20</b>
<b>9. Appendices.....</b>	<b>21</b>

## 1. Introduction

Prostate cancer (PCa) is the most diagnosed non-skin malignancy, and the second leading cause of death, among men in the United States. On January 1, 2007 there were approximately 2,276,112 men alive in the United States who had a history of prostate cancer, and 1 in 6 men born today will be diagnosed with prostate cancer during their lifetime. In order to achieve more effective therapy, focus has recently shifted to the early detection of PCa. While prostate-specific antigen (PSA) monitoring has enabled earlier detection of prostate cancer, the high variability in PSA levels has limited its diagnostic value. Additionally, dynamic changes in molecular, cellular and tissue level processes occur during disease progression and remission, and their quantitative assessment is important for treatment planning and monitoring of treatment efficacy. Measurement techniques currently in use (e.g. biopsy) are invasive, and provide limited spatial and temporal sampling. Improved molecular imaging techniques, that are both quantitative and sensitive, and that can detect processes deep within the human body are required to monitor these changes which may be predictors of treatment outcomes. Hence, the need for a non-invasive, highly sensitive and accurate diagnostic tool for measuring the aggressiveness of prostate cancer is both acute and imperative. Taking all these facts into account, the U.S. Preventive Services Task Force (USPSTF) has recommended that, “research is urgently needed to identify new screening methods that can distinguish nonprogressive or slowly progressive disease from disease that is likely to affect the quality or length of life.” Improved molecular imaging techniques, that are both quantitative and sensitive, and that can detect processes deep within the human body are required to monitor these changes which may be predictors of treatment outcomes. The primary objective of this application is to confirm the feasibility of a microenvironment-responsive multimodal contrast agent (MMCA) for non-invasive, 3D measurement of prostate cancer aggressiveness.

## 2. Keywords

prostate cancer; cancer staging; imaging; MRI; nanomedicine; proteolytic activity; non-invasive detection

## 3. Accomplishments

The goal of the funded project is to develop multimodal and bioprocess-sensitive “smart” magnetic nanoparticles (MNP) capable of detecting dynamic changes in molecular and tissue level processes that occur during prostate cancer progression. Specifically, we are developing MNPs that respond to and are able to monitor and quantify overexpressed proteolytic activity in the tumor microenvironment. Proteolytic processes have been shown to be important for cancer growth, progression, extracellular matrix remodeling and metastasis. The ability to non-invasively monitor this activity would not only enable better treatment planning, but also provide a means to monitor therapeutic effect. The specific aims of this project are: **Aim 1** – Synthesize the microenvironment responsive multi-modal imaging agent (MMIA) and characterize its physical properties (e.g. magnetic susceptibility, particle size distribution, zeta potential, etc); **Aim 2** – *In vitro* characterization of the target selectivity, protease

specificity, and detection sensitivity of the MMIA using low- and high proteolytic activity cell lines; and **Aim 3** – Conduct a pilot *in vivo* animal study to demonstrate the utility of this system for monitoring tumor progression.

According to our statement of work, the objectives for the period of work to date are:

*Task 1 – Synthesis and characterization of the microenvironment-responsive MMIA.*

The subtasks to be done included:

- a. Synthesis of the MMIA components
- b. Optimization of MMIA stability
- c. Assembly of the MMIA/fluorescent probe/targeting agent complex
- d. Characterize the physical properties of the MMIA

*Task 2 – In vitro characterization of target selectivity, protease specificity, and detection sensitivity.* The subtasks to be done included:


- a. Optimization of cancer cell targeting selectivity
- b. Optimization of protease response
- c. Measure selectivity and proteolytic response of MMIA

The accomplishments for each of these subtasks are briefly summarized below. Those completed within the current reporting period are indicated with brackets as “**{current period}**” along with a line down the left margin.


**Task 1 – Synthesis and characterization of the MMIA**

The MMIA to be developed in this project is comprised of superparamagnetic nanoparticles (SPIONs), which serve as a contrast agent for Magnetic Resonance Imaging (MRI), coated with a biopolymer (i.e. starch) to improve biocompatibility, and tagged with prostate cancer-targeting ligands. A significant challenge to translation of nanomedicine from lab bench to the clinical setting arises due to variations in particle behavior *in vivo* as a function of nanoparticle size distribution and surface properties. The vast majority of research in nanomedicine is conducted using particles having a broad size distribution; leading to uncertainty in the pharmacokinetics, biodistribution, and safety risks of the formulations. In order to reduce this barrier, we have developed synthesis and purification procedures that would produce SPIONs of a relatively narrow size distribution.

Our approach was to utilize the size-dependent magnetic properties of the SPIONs and the drag force exerted on a particle, which is also size dependent, to separate a MNP population with a wide size distribution into sub-populations with a more narrow distribution. The feasibility of this approach was first evaluated using a simulation developed in Matlab (MathWorks, Natick, MA). Using this simulation, we were able to determine the conditions required to “purify” particles of a particular size. **Figure 1** provides the predicted traces of MNP ranging in size from 40 nm to 400 nm, under the influence of a magnetic field. Using these results, a prototype separate process was established to take a sample of MNP having a broad size distribution and to produce SPIONs with tighter size control, as shown in **Figure 2**.



**Figure 1.** Predicted particle trajectories for magnetic nanoparticles in the size range of 44 nm (top, orange trace) to 400 nm (bottom, green markers) under the influence of drag and magnetic forces.




**Figure 2.** Average MNP size distributions of six fractions obtained using a prototype device to size-selectively separate SPIONs from a sample having a broad size distribution.

### 3b. Optimization of MMIA stability

**{current period:** For the probe to be effective, it has to be long circulating; accumulate selectively at the tumor site; and respond sensitively to a specific protease activity. To enhance the pharmacokinetic (PK) properties of the probe, we modified the surface of the MNP with polyethylene glycol, a polymer frequently utilized to improve stability of nanoparticles. We assessed size stability of the PEGylated MNP (PEG-MNP) in complete culture media, which contains proteins and other components found in blood plasma, using dynamic light scattering and performed *in vitro* experiments to mimic the first two steps (protein adsorption and macrophage uptake) of the reticuloendothelial system (RES) clearance process.

The starch coating of 50 nm and 100 nm SPIONs was crosslinked and coated with amine groups, and then functionalized with NHS-polyethylene glycol (PEG) of varying molecular weight (i.e., 2k, 5k or 20k Da) as shown in **Scheme 1**.



**Scheme 1.** Surface modification of starch-coated SPIONs into aminated and PEGylated SPIONs.

PEG coatings are often utilized on nanoparticles for their good biocompatibility and favorable chemical properties that enable further modifications. Since the coating itself may completely change the toxicity profile of SPIONs, SPIONs with a variety of surface coatings were tested, including starch-coated SPIONs, aminated SPIONs and finally PEGylated SPIONs. Analysis of SPIONs by transmission electron microscopy (TEM) and Fourier transform infrared spectroscopy (FTIR), and measurement of their magnetic properties provided results similar to that already in the literature, confirming successful modification, and are not repeated here. Some physicochemical characteristics of the 10 different SPIONs tested, however, are summarized in **Table 1**.

**Table 1.** Mean hydrodynamic diameter (HD) and zeta-potential (ZP) of SPIONs in deionized water and in Ham's F-12K culture media supplemented with 10% FBS.


Sample	In deionized water, at 37°C			In supplemented Ham's F-12K cultre media, at 37 °C					
	HD (nm)	PdI	ZP (mV)	1hr		24hrs		72hrs	
				HD (nm)	PdI	HD (nm)	PdI	HD (nm)	PdI
50 nm SPIONs									
Starch-coated	47 ± 1	0.12	-23 ± 3	36 ± 1	0.25	68 ± 2	0.28	148 ± 4	0.30
Aminated	90 ± 2	0.18	+13 ± 1	57 ± 1	0.32	55 ± 5	0.38	50 ± 3	0.38
2k-PEG	72 ± 3	0.20	+36 ± 1	41 ± 1	0.30	40 ± 1	0.30	40 ± 1	0.31
5k-PEG	71 ± 1	0.20	+34 ± 1	37 ± 2	0.42	36 ± 2	0.41	36 ± 2	0.44
20k-PEG	72 ± 4	0.20	+33 ± 2	35 ± 1	0.48	36 ± 1	0.47	33 ± 2	0.47
100 nm SPIONs									
Starch-coated	92 ± 1	0.09	-4 ± 1	117 ± 1	0.29	461 ± 4	0.70	1133 ± 30	0.19
Aminated	127 ± 5	0.17	+43 ± 1	119 ± 4	0.30	110 ± 3	0.22	108 ± 3	0.22
2k-PEG	117 ± 2	0.14	+36 ± 1	93 ± 1	0.24	95 ± 3	0.23	95 ± 2	0.24
5k-PEG	126 ± 4	0.14	+37 ± 1	103 ± 2	0.25	102 ± 2	0.24	114 ± 2	0.29
20k-PEG	154 ± 5	0.12	+32 ± 1	122 ± 3	0.26	117 ± 3	0.26	146 ± 2	0.36

The hydrodynamic diameters of both starch SPIONs were in close agreement with specifications provided by the manufacturer. After crosslinking of the starch coating and its amination, the mean hydrodynamic diameter of both 50 and 100 nm SPIONs increased significantly, possibly due to aggregation and/or due to loss of smaller particles during the processing. PEGylation further increased the hydrodynamic diameter as expected, but the effect of PEG molecular weight (2k, 5k, or 20k) varied between the 50nm and 100nm SPIONs. The effect on 50 nm particles was especially non-uniform as the aminated particles yielded the largest size, possibly due to aggregation. The hydrodynamic diameters of SPIONs were also evaluated when suspended in supplemented Ham's F-12K culture media at 37°C, the conditions employed for in vitro studies, with incubation times of 1, 24 and 72 hours. The hydrodynamic diameters of starch-coated 50nm and 100nm SPIONs were observed to increase with time, whereas the size of aminated, 2k-PEG and 5k-PEG SPIONs, and 50nm 20k-PEG SPIONs remained relatively constant over time. A moderate increase of the hydrodynamic diameter was noticed for 100 nm 20k-PEG SPIONs.

The surface charge of SPIONs gives an indication of their colloidal stability and may also further affect their cellular uptake. In one study, it was demonstrated that anionic nanoparticles, showing a high affinity for cell membranes, were captured more efficiently by cells than bare (dextran-coated) iron-oxide nanoparticles. In deionized (DI) water, starch-coated SPIONs displayed a negative to near neutral zeta potential while the aminated and PEGylated particles showed a high positive surface charge. Surprisingly, a higher zeta potential was observed for the PEGylated 50nm SPIONs compared to the aminated 50nm SPIONs. The PEG layer would be expected to mask some of the surface charge and it is unclear why this was not observed, although measurements were repeated. Aggregation seen with the aminated SPIONs may have had some contribution to this result.


It was confirmed that the SPIONs had a PEG content of up to  $245 \pm 7$  nmol PEG/mg Fe. Next, *in vitro* size stability studies were conducted to validate the improved stability of our PEGylated SPIONs. The particles were incubated in cell culture media containing fetal bovine serum (FBS), to mimic their exposure to opsonizing proteins in the blood, and the particle size measured by dynamic light scattering (DLS) for a period of 24 hours. The results shown in **Figure 3** clearly demonstrate the improved stability of PEGylated particles while the unmodified control, starch particles are observed to rapidly increase in size.





**Figure 3.** Size stability in complete RAW 264.7 cell culture medium (DMEM + 10% FBS + 1% antibiotics) at 37 °C was assessed over a period of 22 hours using dynamic light scattering. As shown, PEGylated SPIONs displayed much better size stability over starch SPIONs.

Colloidal stability is a very important feature that is necessary for successful tumor targeting. Particles that aggregate quickly get cleared from circulation quickly. PEGylated SPIONs also demonstrated significantly lower protein binding and markedly reduced macrophage uptake (**Figure 4a**) than the unmodified starch SPIONs. Among “normal” cells, macrophages have one of the highest rates of particle uptake; uptake of PEGylated SPIONs by healthy cells is therefore expected to be negligible.




**Figure 4. a)** Protein binding in 60% FBS was studied to simulate the first step of SPION clearance from plasma. PEGylation caused a significant drop in protein adsorption; **b)** RAW 264.7 macrophage uptake of starch-coated and PEGylated SPIONs was measured over 24 hours to assess the impact of PEGylation on pharmacokinetic properties.

Our results indicated that PEG-MNPs showed significantly better size stability (i.e. resisted aggregation) and lower protein binding than the unmodified MNP. The MNPs were also incubated for varying time periods with macrophages. As shown in **Figure 4b**, the unmodified MNP were rapidly taken up by the RAW 264.7 macrophage cells, while only limited uptake of PEG-MNP was observed even after 24 hours. Among “normal” cells found in the body, macrophages have one of the highest rates of particle uptake. The synthesized particles are therefore expected to be very stable in

physiological media and uptake of PEG-MNPs by healthy cells is expected to be negligible. }

### 3c. Assembly of the MMIA/fluorescent probe/targeting agent complex

While the previously stated results showed that stable MNPs have been developed and their uptake by “normal” cells minimized, it is also necessary that these particles target and accumulate in cancer cells. To induce uptake of MNPs by prostate cancer cells, we functionalized the surface with a tumor-targeting peptide (F3 peptide), which selectively binds to nucleolin present on the surface of tumor cells and endothelial cells of angiogenic tumor blood vessels. While nucleolin is present in all cells, it is only found on the extracellular surface of cancer cells – providing a means to target these cells. In order to determine whether the density of the targeting peptide affects the targeting efficiency, MNPs with a high density of F3-peptide, an intermediate density, and no targeting peptide were incubated with PC3 prostate cancer cells and the particle uptake measured after 1 and 4 hours. As shown in **Figure 5**, the F3-labelled MNPs should significantly greater targeting of the PC3 cells compared to the non-targeted, PEG-MNP. It should be noted that the F3-MNP did not show significant uptake by “normal” cells (data not shown), demonstrating our ability to maximize the target selectivity of the MNP to cancer cells.




**Figure 5.** The conjugation of F3 tumor targeting peptide enhances MNP uptake by PC3 prostate cancer cells compared to the non-targeted PEG-MNP.

### Task 2 – *In vitro* characterization of selectivity, protease specificity, and detection sensitivity


{current period: In order to insure that administered doses of MNP do not elicit toxic effects, the cytotoxicity of the MNPs were measured against the Chinese hamster ovary (CHO-K1) cell line. CHO cells were selected for this particular assay because of their

extensive use in evaluating cytotoxicity of active agents for approval by the U.S. Food & Drug Administration (FDA). As shown in **Figure 6**, the results indicate that toxicity of the MNP is dependent on particle size, surface chemistry, concentration, and duration of exposure. No significant toxicity was observed after a relatively short exposure of just 24 hrs with any of the MNPs. While significant toxicity was observed when MNP were incubated with cells for 72 hours, this was strongly concentration dependent. In order to minimize background signal, it is desirable that the MNP clear from blood circulation relatively quickly but remain sufficiently long for tumor accumulation. Future *in vivo* studies will determine the plasma pharmacokinetics of the MNP but, according to past experience, the circulation half-life is expected to be less than 12 hours. Additionally, particle concentration is expected to be less than 100  $\mu\text{g Fe/mL}$ , a concentration below which the MNP modified with 2kDa PEG showed negligible toxicity.

### A. 72 hour incubation




### B. 24 hour incubation



**Figure 6.** Cytotoxicity of superparamagnetic iron-oxide nanoparticles (SPIONs) in Chinese Hamster Ovary (CHO-K1) cells evaluated with the (a) tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) after a) 72 hour and b) 24 hour incubation with MNPs having a


“starch” coating, a positively-charged “aminated” coat, or PEG (MW 2k, 5k, or 20k Daltons) coating. The 50% viability line and a doxorubicin positive control are shown for comparison.

For prostate cancer targeting, in the event that the F3 peptide proves to be non-specifically taken up by non-target cells during *in vivo* studies, additional peptides were identified for possible targeting of the MMIA. Several targeting ligands that demonstrate high affinity for PC3M and LNCaP prostate cancer cells, while showing minimum binding to RWPE-1 normal prostate cells. In this study, phage particles having a specific peptide sequence on the surface, as listed below, were incubated for one hour with: 1) highly metastatic PC3-M prostate cancer cells; 2) slow growing LNCaP prostate cancer cells; 3) normal prostate cells (RWPE-1); and 4) serum control. The cells were then rinsed with PBS and the amount of bound phage determined as a ratio of the initial loading, as shown in **Figure 7**. These results provide us with candidate targeting ligands that would enable the targeting of both metastatic PC3-M and slow-growing LNCaP prostate cancer cells. This would enable the use of a single targeted MMIA for detection of proteolytic in aggressive PC3-M tumors as well as non-aggressive controls. The ligands labeled P1-P6 were found to have especially high affinity for the PC-3M cells, while also showing varying specificity for the LNCaP and RWPE-1 cells.




**Figure 7.** Relative binding affinity of prospective targeting ligands with PC3-M and LNCaP prostate cancer cells, compared to normal prostate cells and serum controls. Several ligands with high selectivity for prostate cancer have been identified.

Binding of targeting ligands, labeled P1-P6 in Figure 7, to PC3M cells was further visualized using fluorescence microscopy, as shown in **Figure 8**. The results indicated that particles P3, P4, and P5 bound to the PC3-M cells to a greater extent than the other particles. Further visualization and characterization of their binding to the LNCaP and normal prostate cells are ongoing but these promise to be good alternatives to F3 for targeting of MNPs.



**Figure 8.** Fluorescent images showing the *in vitro* binding of six different targeting ligands (red markers) to PC3-M cells (nucleus stained blue).

In addition to the targeting of the MNP to cancer cells, an important component of the proposed work is to label the particles with a fluorescent dye whose release is triggered by proteolytic activity. The fluorescently labeled peptide 5-TAMRA-SGKGPRQITAGGC-amide was conjugated to the surface of the MNP using maleimide chemistry. To determine its response to proteolytic activity, the MNP-peptide was incubated with varying concentrations of the protease TrypLE Express (Life Technologies, Grand Island, NY) for 15 minutes, centrifuged, and the fluorescence of the supernatant measured at 546/579 (characteristic of 5-TAMRA fluorescent dye). As seen in **Figure 9**, the concentration of the protease correlated with the release of 5-TAMRA from the surface of the MNP. Based on these preliminary results, we are currently evaluating the ability of this system to detect activity of legumain and matrix metalloproteinase 9 (MMP-9). Legumain and MMP-9 are important tumor-associated proteases, overexpressed in the prostate cancer microenvironment, and the level of which is associated with metastatic potential of the cancer.



**Figure 9.** Fluorescently labeled peptides were conjugated to the surface of MNP and their initial release rate measured, as ratio of fluorescence signal at 546 nm and 579 nm, with varying concentrations of trypsin protease. Fluorescence intensity was measured after a 15 minute incubation.


**{current period:** The next step would be to evaluate the MMIA with an appropriate cell line expressing matrix metalloproteinase (MMP). While MMP has been shown to be highly expressed by PC3 cells *in vivo*, PC3 do not secrete measurable quantities of MMP in *in vitro* cultures. While the ultimate goal is to target prostate cancer cells, the human fibrosarcoma HT-1080 cell line is one of the most frequently used cell types for MMP research *in vitro* and *in vivo*. This is primarily because it is one of the few cell lines to express MMP *in vitro*. Moreover, HT-1080 tumors grow quickly *in vivo* and are very well vascularized, enabling penetration by nanoparticles. We conducted gelatin zymography studies on HT-1080 serum-free conditioned media, which confirmed the secretion of gelatinase, an MMP, as shown in **Figure 10**.



**Figure 10. A)** Illustrates the main steps in gelatin zymography. **B)** Gelatin zymography on serum-free conditioned media and lysate of HT-1080 cells confirmed gelatinase secretion by HT-1080 cells.

Having confirmed the secretion of MMP by HT-1080 cells, we then sought to select an appropriate targeting ligand for HT-1080 cells. This would enable the use of HT-1080 cells as a well-characterized, positive control for the *in vivo* studies. The overexpression of  $\alpha_v\beta_3$  integrin, an important tumor biomarker, on the surface of HT-1080 cells has been previously reported in the literature. The RGD motif, found in several extracellular proteins, is known to be a potent integrin  $\alpha_v\beta_3$  antagonist and cyclic forms of the RGD (cRGD) peptide has been widely utilized as an  $\alpha_v\beta_3$  integrin targeting ligand. To induce uptake by HT-1080 cells, the surface of MNPs were functionalized with cRGD through a heterobifunctional PEG (MAL-PEG-NHS). The particles were labeled cRGD-PEG-SPION and a control that lacked cRGD was also synthesized, and labeled PEG-SPION.

Prior to running cell uptake studies, we tested the size stability of cRGD-PEG-SPION in HT-1080 complete culture medium. **Figure 11A** shows that the particles were very stable over a period of 72 hours. Next, we investigated whether the quantitative BCA protein assay can be used to measure HT-1080 cell number. An excellent linear fit was generated (**Figure 11B**), which ensured that we are able to correct for the number of cells in different wells. Finally, cellular uptake of the SPION by HT-1080 cells was conducted using the ferrozine assay for SPION quantification and the BCA assay for cell quantification. cRGD-PEG-SPION displayed significantly higher uptake over control PEG-SPION (**Figure 11C**). This was an important result that confirmed our ability to actively target HT1080 cells and provided a positive control for future studies.



**Figure 11.** cRGD studies - **A.** cRGD-PEG-SPION showed excellent size stability in HT-1080 complete culture medium over a period of 72 hours. **B.** Standard curve for BCA protein quantification at different



HT-1080 cell number. **C.** cRGD-PEG-SPION displayed significant HT1080 cell uptake versus control PEG-SPION.

### **Opportunities for training and professional development**

During the past period of this project, two graduate students, a Master student and one PhD student, have been trained in the synthesis and characterization of MNPs, as well as in the techniques of cell culture work. The graduate students have also presented their work and attended talks at several conferences, including:

- 2013 AIChE Annual Meeting, San Francisco, CA
- 2014 AIChE Annual Meeting, Atlanta, GA
- 2015 Science and Technology Open House, Montgomery, AL
- 2015 Auburn Univ. Research Initiative in Cancer (AURIC) Meeting, Auburn, AL

The Master's student has graduated and is currently pursuing a PhD degree at Northwestern University.

Additionally, four undergraduate students have been mentored in the lab during the funded period. One undergraduate student has since graduated and is currently attending the medical school at the University of Alabama - Birmingham. Two other undergraduate students graduate recently and accepted positions in the commercial sector. The fourth student has been accepted into the PhD program in chemical engineering at the University of Notre Dame (to begin in Fall 2016).

### **Dissemination of results to communities of interest**

Nothing to report

### **Plan for the next report period**

Much of the work proposed for Task 1 of the project (i.e. synthesis and optimization of the MNP) has been completed and some of the work for Task 2 has been initiated (e.g. *in vitro* studies of cancer cell target specificity and protease specificity). During the next report period, we will continue to evaluate the MNP with *in vitro* assays by extending the proteolytic activity response to legumain and MMP-9 proteases and conduct more rigorous evaluation using prostate cancer and normal prostate cell lines. We also plan to initiate some of the proposed *in vivo* work. **The project is currently on schedule with the timeline provided in the statement of work.**

## **4. Impact**

Nothing to report.




## 5. Changes/Problems

**{current period:** The goal of this project is to utilize two different imaging modalities for quantification of proteolytic activity. One of the challenges in accomplishing this task is the co-registration of the two different data sets to achieve spatial and temporal alignment. During the past year, new resources have become available at Auburn University that enable us to conduct multispectral optoacoustic tomographic imaging.


Multispectral optoacoustic tomography (MSOT) is a highly promising biomedical imaging technology that combines the rich contrast of optical imaging with the high resolution and great penetration depth of ultrasound imaging. MSOT detects ultrasonic waves generated by chromophores following absorption of light. Back-projection or model-based algorithms are then used to reconstruct images at a particular wavelength. By illuminating a target with different wavelengths in the 680-980 nm range, MSOT can resolve the contributions of different chromophores known to be present in a particular sample based on their unique absorption spectra. This capability provides this project with a means to measure both signals (i.e. that of the MNP concentration and proteolytic activity), simultaneously in a single instrument. Such imaging would dramatically improve the probability of successfully achieving the project goals. It would also serve as a good model of future multi-modal imaging systems that could be utilized with the developed MMIA.

As a quick proof-of-concept study, tissue-mimicking agar gels (2 cm diameter) were developed with two cylindrical channels (3 mm in diameter): one to hold a sample containing Cy5-tagged MNP and the other for a blank control. The phantoms were imaged at the following wavelengths: 680, 700, 730, 750, 800, 850, and 900 nm. Image reconstruction was done using a back-projection algorithm. **Figure 12** shows a single cross-sectional image, taken from 3D tomographic data, with the signal intensity representing the total photoacoustic signal for Cy5-MNP at different wavelengths. This simply confirmed that the MNP did in fact provide a positive MSOT signal.



**Figure 12.** Photoacoustic signal generated at different wavelengths for Cy5-MNP

Because of the spectral profile of the Cy5 dye, the strong photoacoustic signal at 680 nm and lower signal above 800 nm was expected. Phantom gels containing varying concentrations of Cy5-MNP were subsequently imaged and the measured signal intensity correlated with concentration of the MNPs. As shown in **Figure 13**, a strong correlation was observed between the total photoacoustic signal and MNP concentration, which demonstrates our ability to use this technique for quantification.



**Figure 13.** Photoacoustic standard curves for Cy5-MNP at different wavelengths.

Given this positive result and the potential for the MSOT technique to significantly enhance the objectives of this project, we would like to propose the addition of this imaging modality to the statement of work. This would be done in addition to the MRI imaging already proposed and would therefore not constitute a drastic change to the goals of the project. }

## 6. Products

Rogers HB, Anani T, Choi YS, Beyers RJ, David AE. Exploiting size-dependent drag and magnetic forces for size-specific separation of magnetic nanoparticles. *Intl J of Molecular Sciences* (2015) 16:20001-19.

Anani T\*, Choi YS\*, David AE. Magnetic nanoparticles for non-invasive quantification of prostate cancer aggressiveness. 2014 AIChE Annual Meeting, Atlanta GA. 2014 Nov. (oral presentation)

Rogers HB, Anani T, Read C, David AE. Magnetic nanoparticles as multimodal contrast agents for the diagnosis of prostate cancer. 2013 AIChE Annual Meeting, San Francisco CA. 2013 Nov. (poster presentation)

Anani T, Read C, Rogers H, Choi YS, David AE. Magnetic nanoparticles as multimodal contrast agents for measuring prostate cancer aggressiveness. 2013 AIChE Annual Meeting, San Francisco CA. 2013 Nov. (poster presentation)

## 7. Participants & Other Collaborating Organizations

### Individual Participants:

**Name:** Allan E. David  
**Project Role:** PI  
**Person month worked:** 1  
**Contribution to project:** Overall planning, data analysis, trouble shooting, and monitoring of graduate students

**Name:** Tareq Anani  
**Project Role:** Graduate student  
**Person month worked:** 12  
**Contribution to project:** Synthesis of MNPs and cell culture studies  
**Funding support:** Partially supported by Auburn University Research Initiative in Cancer Fellowship

**Name:** Alan Hanley  
**Project Role:** Graduate student  
**Person month worked:** 6  
**Contribution to project:** Synthesis and characterization of nanoparticles

**Name:** Young Suk Choi  
**Project Role:** Postdoctoral fellow  
**Person month worked:** 2  
**Contribution to project:** Training of graduate students in cell culture techniques and identification of prostate cancer targeting ligands  
**Funding support:** Partially supported by Auburn University Research Initiative in Cancer

### Active other support of PI

**Sponsor:** Found Animals Foundation  
**Project Title:** Ablation of pituitary gonadotropes by DNA vaccine targeting GnRH receptor: proof of concept study in mice

PI/Co-PIs: Samoylova T; David AE  
Period: 1/1/2015 – 12/31/2015

Sponsor: Auburn University Intramural Grants Program  
Project Title: Protecting animal and human health by using advanced molecular methods to enhance vaccine technology  
PI/Co-PIs: Johnson A; David AE; Baker H; Roberts MS; Van Kampen KR  
Period: 5/1/2015 – 4/30/2017

Sponsor: College of Vet. Med. – Animal Health and Disease Research Prog. (CVM-AHDR)  
Project Title: Achieving contraception of animals via enhanced antibody responses to phage-GnRH constructs  
PI/Co-PIs: Samoylova T; David AE  
Period: 1/1/2015 – 12/31/2015

Sponsor: Southern Company  
Project Title: Hierarchical micro/nano-structures for condensation enhancement  
PI/Co-PIs: Bhavnani S; David AE; Ashurst R  
Period: 9/15/2014 – 1/31/2016

**Involved organizations as partners**  
Nothing to report

**8. Special Reporting Requirements**  
Nothing to report

## 9. Appendicies:

Original copy of manuscript (see next page)

Article

## Exploiting Size-Dependent Drag and Magnetic Forces for Size-Specific Separation of Magnetic Nanoparticles

Hunter B. Rogers <sup>1</sup>, Tareq Anani <sup>1</sup>, Young Suk Choi <sup>1</sup>, Ronald J. Beyers <sup>2</sup> and Allan E. David <sup>1,\*</sup>

<sup>1</sup> Department of Chemical Engineering, Auburn University, 212 Ross Hall, Auburn, AL 36849, USA; E-Mails: hunterrogers2014@u.northwestern.edu (H.B.R.); tba0008@tigermail.auburn.edu (T.A.); yzc0036@auburn.edu (Y.S.C.)

<sup>2</sup> Auburn University MRI Research Center, Auburn, AL 36849, USA; E-Mail: rjb0018@auburn.edu

\* Author to whom correspondence should be addressed; E-Mail: aedavid@auburn.edu; Tel.: +1-334-844-8119.

Academic Editor: O. Thompson Mefford

Received: 30 June 2015 / Accepted: 10 August 2015 / Published: 21 August 2015

---

**Abstract:** Realizing the full potential of magnetic nanoparticles (MNPs) in nanomedicine requires the optimization of their physical and chemical properties. Elucidation of the effects of these properties on clinical diagnostic or therapeutic properties, however, requires the synthesis or purification of homogenous samples, which has proved to be difficult. While initial simulations indicated that size-selective separation could be achieved by flowing magnetic nanoparticles through a magnetic field, subsequent *in vitro* experiments were unable to reproduce the predicted results. Magnetic field-flow fractionation, however, was found to be an effective method for the separation of polydisperse suspensions of iron oxide nanoparticles with diameters greater than 20 nm. While similar methods have been used to separate magnetic nanoparticles before, no previous work has been done with magnetic nanoparticles between 20 and 200 nm. Both transmission electron microscopy (TEM) and dynamic light scattering (DLS) analysis were used to confirm the size of the MNPs. Further development of this work could lead to MNPs with the narrow size distributions necessary for their *in vitro* and *in vivo* optimization.

**Keywords:** field-flow fractionation; iron oxide nanoparticles; size separation; magnetic nanoparticles; nanomedicine

---

## 1. Introduction

Nanomedicine is a broad area of research focused on the utilization of nanomaterials for the diagnosis, treatment, and prevention of diseases [1]. Biomedical applications present a unique opportunity to create engineered nanomaterials with highly controlled properties and functions that are comparable in scale to biological molecules and structures [2]. This is especially relevant for the fields of biomimetic nanomaterials, targeted drug delivery systems, and diagnostic imaging agents [3,4]. In contrast to the ever-growing list of nanomaterials researched for medical applications, the number of technologies actually approved for clinical use is relatively small. This is, in part, due to an overall paucity of fundamental knowledge and a lack of understanding of how the physical and chemical properties of nanomaterials affect their interactions with biological systems, and the associated uncertainty in their safety and toxicity profiles [5].

It is known that the behavior of nanomaterials within biological environments, including their stability and biodistribution, is dependent on their chemical composition and physical properties, such as size and geometry [6]. For nanomaterials to achieve their full potential in clinical applications, the fundamental principles governing their physio-chemical properties and the effects of these properties on physiological processes must be determined. However, obtaining nanoparticles of homogenous composition, either by finely controlled synthesis or through separation processes, has proven to be challenging. Particle size, in particular, can have a significant effect on the fate of nanoparticles once introduced into the body. For example, it has been shown that nanomaterials smaller than 6 nm are filtered out by the kidneys while those larger than 200 nm are more avidly taken up by macrophages and found to accumulate within the liver and spleen [7–9]. The biodistribution and pharmacokinetics of nanomaterials can also be affected by disease states. With cancer, for example, tumors typically possess a leaky vasculature and altered lymphatic drainage that results in the enhanced permeability and retention (EPR) effect, which enables extravasation of nanomaterials into the tumor microenvironment, with particles of size less than 200 nm typically providing greatest tumor penetration [10,11].

Magnetic nanoparticles (MNPs), specifically those composed of iron oxide, have been studied extensively for use in a variety of applications in nanomedicine, especially in the area of drug delivery and biomedical imaging [12–15]. In fact, several MNP formulations have been approved for clinical application as imaging contrast agents (e.g., Feridex<sup>®</sup>/Endorem<sup>®</sup>, Resovist<sup>®</sup>/Cliavist<sup>®</sup>, and Sinarem<sup>®</sup>/Combidx<sup>®</sup>) but commercial production has been halted due to poor clinical performance [16–18]. An improved understanding of the structure-property-performance relationships of MNPs could significantly improve their clinical application. While synthesis of iron oxide nanoparticles having monodisperse diameters less than 30 nm is well established, the synthesis of larger, monodisperse, iron oxide nanoparticles has proved challenging and greatly limited their optimization for biomedical applications. [19–21]. Batch-to-batch variability in nanoparticle production and broad size distributions raise safety concerns for clinical application due to the dependence of pharmacokinetics and biodistribution on the particle's physical and chemical properties [22]. In order to promote the clinical translation of MNPs, methods must be developed that either allow for synthesis of homogenous nanoparticles or enable their size-selective fractionation post-synthesis.

One potential solution to this problem is the use of magnetic field-flow fractionation (mFFF). This process, based on the separation of particles via the combined effects of the size-dependent drag

and magnetic forces, was first reported in 1980 by Vickrey and Garcia-Ramirez who wrapped Teflon tubing around a small electromagnet in an attempt to separate nickel complexes of bovine serum albumin from a fluid [23]. While a number of studies in literature report the use of various mFFF approaches, these primarily focus on the use of mFFF for characterizing small volumes of micro- or nano-particles or for the separation of magnetic particles from non-magnetic materials [24–26]. Very little attention has been given to mFFF as a size-specific separation technique for magnetic nanoparticles, especially for nanoparticles within the size range relevant for biomedical applications. The use of high gradient magnetic separation (HGMS) has been used by several groups to separate colloid suspensions of large magnetic nanoparticles, but the focus was not necessarily on the sorting of a polydisperse MNP suspension into multiple samples having narrower and controlled size distributions [27,28]. Beveridge *et al.* did report the use of a differential magnetic catch and release as a size-selective separation technique; however, their work focused on magnetic nanoparticles with diameters less than 20 nm [29]. The focus of this study is on the separation of MNPs with a hydrodynamic diameter in the range of 50–400 nm, which have potential biomedical application. Several prototypes for MNP separation were tested and the polydisperse MNPs ultimately separated into fractions having a narrower size distribution. This ability to separate magnetic nanoparticles according to their size ultimately enables the fundamental studies required to advance the use of magnetic nanoparticles in medicine.

## 2. Theory

Magnetic nanoparticles introduced into a mFFF system experience drag and magnetic forces in proportion to particle size. Very small particles, such as those on the nanoscale, also exhibit random Brownian motion, which can significantly affect nanoparticle behavior. For small, spherical particles in a fluid possessing a small Reynolds number ( $Re < 1$ ), the drag force  $F_D$  can be described using Stokes drag, which is defined as:

$$F_D = 6\pi\eta rv \quad (1)$$

where  $\eta$  is the fluid viscosity,  $r$  is the hydrodynamic radius of the particle, and  $v$  is the fluid velocity [30]. The drag force is therefore directly proportional to the hydrodynamic radius of the particle. The magnetic force  $\vec{F}_M$  experienced by a magnetic particle within an applied magnetic field  $\vec{B}$  is given by the following equation:

$$\vec{F}_M = (\vec{m} \cdot \nabla) \vec{B} \quad (2)$$

where  $\vec{m}$  is the magnetic moment of the particle, calculated using the equation:

$$\vec{m} = \rho V \vec{M} \quad (3)$$

where  $\rho$  is the particle density,  $V$  is the volume of magnetic material in the particle, and  $\vec{M}$  is the magnetization of the particle [31]. According to Equation (3), the magnetic force experienced by a particle is proportional to  $\sim r^3$ —increasing with size of the MNP, while the magnitude of the drag force (Equation (1)) is proportional to  $r$ . This dependence of the drag and magnetic forces on particle size provides a means to manipulate magnetic nanoparticles in a size-dependent manner.



As mentioned previously, for very small particles in a fluid, molecular collisions result in a source of diffusion known as Brownian motion. The Brownian diffusion length,  $L_D$ , traversed by a particle in two-dimensions over some time interval  $dt$  is approximated by the equation:

$$L_D = \sqrt{4D \, dt} \quad (4)$$

where  $D$  is the particle-specific diffusion coefficient, defined as:

$$D = \frac{k_B T}{6\pi\eta r} \quad (5)$$

where  $k_B$  is the Boltzmann's constant and  $T$  is the absolute temperature [32]. This relation shows that diffusion due to Brownian motion is also size-dependent and that the rate of diffusion decreases with increasing particle size. Taken together, these equations can be used to predict the movement of MNPs under the influence of drag and magnetic forces and Brownian motion.

### 3. Results and Discussion

#### 3.1. Modeling the Effects of Drag and Magnetic Forces

A Matlab simulation was developed to study the feasibility of separating magnetic nanoparticles of sizes between 50 and 400 nm using the proposed approach. The simulation was based on a proposed experimental design that included 1.6 mm I.D. tubing of length 60 mm running parallel to a magnet, as shown in Figure 1. A Y-split at the end of the tubing ( $x = 60$  mm) facilitated separation of MNPs based on their  $y$ -position. If the final  $y$ -position of a particle was greater than zero (center of the channel is at  $y = 0$ ) then it was considered to be in Fraction 1, while those at or below the line were considered to be in Fraction 2. The magnetic field was derived from a series of five  $\frac{1}{4}$ " diameter  $\times$   $\frac{1}{4}$ " length cylindrical neodymium magnets (Cat No.: D44-N52, K & J Magnetics, Pipersville, PA, USA) spaced 7.5 mm apart, as shown in Figure 2a. The magnetic flux density map (Figure 2a) was generated using data provided by the manufacturer and assuming non-interacting magnets.


#### Simulation of Particle Trajectories

Particle trajectories were predicted by force balance, to determine acceleration and velocity, on a single particle at some coordinate ( $x_{MNP}(t)$ ,  $y_{MNP}(t)$ ). The new position of the particle, after a time-step  $dt$ , was determined using the following equations:

$$x_{MNP}(t + dt) = x_{MNP}(t) + L_{Dx} + \left[ \frac{v_x(t) + v_x(t + 1)}{2} \right] dt \quad (6)$$

$$y_{MNP}(t + dt) = y_{MNP}(t) + L_{Dy} + \left[ \frac{v_y(t) + v_y(t + 1)}{2} \right] dt \quad (7)$$

where  $L_{Dx}$  and  $L_{Dy}$  refer to the diffusion length in the  $x$  and  $y$ -direction, respectively, and  $v_x$  and  $v_y$  are the respective velocities in the  $x$  and  $y$ -directions. At each time step, the Brownian diffusion of particles was determined by assigning a random fraction of the size-dependent diffusion length,  $L_D$ , to the  $x$ - and  $y$ -directions.



**Figure 1.** Illustration of the proposed experimental setup and the force balances experienced by two differently sized magnetic nanoparticles as they flow through the system. Green arrows represent the magnetic force ( $F_M$ ) and red arrows represent the drag force ( $F_D$ ). At position (1), the two MNPs are introduced to magnetic field in flow at the wall opposite the magnet. At a later time, the two particles reach position (2) and have separated from each other in the  $y$ -direction due to the increased magnetic force experienced by the larger MNP. Upon reaching the end of the channel at position (3), the larger of the two particles has traversed past the midline of the channel ( $y = 0$ ) and will therefore be collected in Fraction 2. The smaller particle remains above  $y = 0$  and will be collected in Fraction 1.

To mimic the injection of particles through a small capillary tube, the model initially located MNPs at randomly generated distances no greater than 100  $\mu\text{m}$  from the wall opposite the magnets. Each simulation run consisted of 100 nanoparticles, with the particle size distribution determined by data obtained using DLS (Figure 2b).

Using this model, it was predicted that magnetic nanoparticles within the size range of interest could indeed be manipulated in a size-dependent manner using flow through a magnetic field. Three conditions, with the tubing placed 7.5, 10.0, and 11.5 mm from the magnet pole face, were simulated with the fluid velocity and viscosity kept constant at 0.018 m/s and 1.005 mPa·s, respectively. This spacing was predicted to give three distinct size separations, as seen in Figure 2c–e. At a magnet distance of 7.5 mm, a majority of the nanoparticles with sizes between 50 and 100 nm would be in Fraction 1, while larger sized particles will be collected in Fraction 2. Comparatively, at a distance of 11.5 mm it is predicted that nanoparticles with sizes between 50 and 150 nm will be collected in Fraction 1 and the majority of nanoparticles between 200 and 400 nm will end up in Fraction 2. Based on these results, we then attempted to validate our model by replicating the simulation conditions experimentally.





Figure 2. Cont.



**Figure 2.** (a) Digital image of the sequence of magnets used for the simulation and validation experiments and the magnetic field map generated, using data from the manufacturer, for a series of five non-interacting  $\frac{1}{4}$ " diameter cylindrical magnets; (b) DLS size distribution of original iron oxide nanoparticle suspension; Predicted particle trajectories and resulting size distributions for original MNP (red), Fraction 1 (blue) and Fraction 2 (green) for magnet distances of (c) 7.5 mm; (d) 10 mm; and (e) 11.5 mm. Particle trajectory data sets based on MNP size of  $-44$ ,  $-51$ ,  $-59$ ,  $-68$ ,  $-79$ ,  $-91$ ,  $-106$ ,  $-122$ ,  $-142$ ,  $-164$ ,  $-190$ ,  $-220$ ,  $+255$ ,  $+295$ ,  $+342$  and  $+396$  nm.

### 3.2. Experimental Validation of the Mathematical Model

A magnetic separation prototype, as seen in Figure 3a, was developed to reproduce the conditions of the simulation. As with the mathematical model, 1.6 mm I.D. tubing was used to replicate the 2D channel and 100  $\mu$ m I.D. tubing was used to inject MNPs into the mobile phase at the wall opposite the magnets. Similar to conditions used in the simulation, the magnetic block was placed at distances of 7.5, 10, and 11.5 mm away from the center of the tubing, and a steady fluid flow velocity of 0.018 m/s was maintained using two syringe pumps.

Repeating the simulated runs with the experimental setup, we obtained the samples pictured in Figure 3b. A clear visual difference was observed in the samples taken from Fraction 1 (left column) and Fraction 2 (right column) for the three runs that seemed to coincide with the predicted behavior. For example, in the case of the magnets placed 11.5 mm from the center of the tube (pictured top), it was predicted that a majority of the particles would be found in Fraction 1, with only the larger particles ( $>200$  nm) being found in Fraction 2. Images in Figure 3b seem to agree with this result with the concentration in Fraction 1 apparently higher than that of Fraction 2, as evidenced by the increased coloration. Analysis of the samples using DLS, however, showed that all samples having sufficient

particle concentration for measurement (*i.e.*, the colored samples) possessed size distributions nearly identical to that of the original solution, as seen in Figure 3c–e. Samples not showing the yellow coloration (*i.e.*, Fraction 2 for 11.5 mm and Fraction 1 for 7.5 mm) were found to be too dilute to obtain a reliable DLS measurement.





Figure 3. Cont.



(e)

**Figure 3.** (a) Digital image of magnetic separation prototype developed to replicate the conditions of the MATLAB simulation; (b) Digital image of Fraction 1 (**left**) and Fraction 2 (**right**) samples collected from the magnet distances of, from top to bottom, 11.5, 10, and 7.5 mm; (c–e) Size distributions of the obtained samples using distances of 7.5, 10, and 11.5 mm compared to that of the original MNP suspension.


As mentioned, the MATLAB simulation was created as a simple model of the proposed system and it therefore did not account for particle-particle interactions and used a system of magnets assumed to be non-interacting for simplicity. In reality, interactions between the magnets would certainly be present and would alter the magnetic forces experienced by MNPs. Additionally, it is well established that increasing particle concentrations lead to a decrease in inter-particle distance and an increase in particle–particle interactions [33]. In this study, the concentration of MNP suspension injected into the mobile phase was significantly concentrated to ensure final concentrations obtained were appropriate for DLS analysis. This resulted in the particles behaving as a ferro-fluid rather than individual particles and limited size-specific separation. Repetition of these studies at lower MNP concentrations, where particle-particle interactions would be minimized, on the other hand, yielded samples too dilute for characterization. Therefore, it was concluded that magnetic separation of particles suspended in a flow field is unlikely to produce the desired separation on a reasonable scale using this approach.

### 3.3. Successful Size-Selective Elution of Iron Oxide Nanoparticles from an Applied Magnetic Field

Due to the failure of the initial experiments, we then reversed the approach and used flow fields to elute MNPs that were held by a magnetic field. Since the magnetic force is dependent on nanoparticle size, the force required to counteract the magnetic force on two differently-sized MNPs will be lower for the smaller particle. In this case, the counteracting force is the fluid drag force, which is modulated by adjusting the flow rate of the mobile phase.

This was accomplished by creating a simple experimental setup, called the MagCoil, composed of a 18.5" length of 1/8" I.D. tubing wrapped around the entire 2" length of a Grade N42 diametrically magnetized neodymium cylinder (Model No.: ND039-0, Applied Magnets, Plano, TX, USA), as seen in Figure 4a. An inlet for both the MNP suspension and mobile phase were included at the top and a single outlet at the bottom was used for the collection of samples.





**Figure 4.** (a) Digital image of MagCoil magnetic separation prototype composed of 1/8" I.D. tubing wrapped around the length of a 2" diametrically magnetized cylinder encased in a plastic column for stability; (b) Average size distributions obtained using the MagCoil prototype and flow rates of 10, 20, 30, 40, and 50 mL/min, as well as the flushed particles (LO) calculated from the results of three separate experimental runs; (c) Box-and-whisker plot comparing the size distributions obtained using the MagCoil, at the varying flowrates, to the original size distribution. Horizontal lines indicate the mean diameter (nm), while the bar indicates standard deviation, and the vertical line the range. Significance determined using a two-tailed, two sample *t*-test ( $n = 90$ ; \*\*\*  $p < 0.001$ ; \*  $p < 0.05$ ; ns—not significant). The large sampling size of DLS ( $>100$  k particle counts/s) leads to a statistically significant result between samples that would seem to be identical otherwise.


After filling the tubing with nanoparticle suspension and allowing them to reach a steady state level of accumulation at the inner wall of the tubing, an initial low flow rate of 0.25 mL/min was introduced to wash away any nanoparticles remaining suspended. DLS measurements of the recovered nanoparticles showed a size distribution similar to the original suspension of nanoparticles (data not shown). A series of increasing flow rates from 10 to 50 mL/min was then applied and samples collected using each of the flow rates for characterization. “Left over” particles, labeled “LO”, that remained in the MagCoil after application of the highest flow rate were then released by removing the magnet and again applying the 50 mL/min flow rate. All experiments were performed in triplicate and the resulting DLS measurements, shown in Figure 4b, are presented as the mean of three experiments. Figure 4c shows the mean hydrodynamic diameter, as well as the standard deviation, range and statistical significance, for each of the size distributions separated out of the original MNP suspension. Samples collected at flowrates of 10, 20, 40 and 50 mL/min and the LO sample, all were statistically different (at least  $p < 0.05$ ) from the original suspension. While the 30 mL/min sample ( $133 \pm 10$  nm) could not be distinguished from the original sample ( $137 \pm 21$  nm), it should be noted that the separated sample has a four-fold smaller variance ( $\sigma^2$ ). It should also be noted that while the DLS technique typically “counts” more than 100 k samples/s for several seconds, an  $n$ -value of 90 was used for statistical analysis.

To confirm the DLS measurements with TEM, samples were again collected with applied flow rates of 10, 40 mL/min, and LO. As shown in Figure 5a, DLS analysis of samples collected from the 10, 40 mL/min, and LO applied flow rates were found to be of size  $96.3 \pm 9.0$ ,  $123.6 \pm 7.9$ , and  $141.5 \pm 10.8$  nm, respectively. These samples were labeled as MNP-96, MNP-124, and MNP-142, respectively. TEM analysis was then performed to both confirm the occurrence of size-dependent separation of the original MNP suspension and for comparison with the obtained DLS results. Figure 5b shows a TEM image of the original suspension, designated as MNP-O. The average size of the original suspension was found to be  $75.4 \pm 47.7$  nm using TEM compared to  $137.2 \pm 20.8$  nm determined using DLS. It is important to note that apparent discrepancy in size is because TEM measurements provide the size of the core diameter while DLS measures the hydrodynamic diameter, which includes the core, surface coating, and any bound solvent. Representative images of each MNP-96, MNP-124, and MNP-142 are given in Figure 5c–e. Analysis of the TEM images showed the average core diameters to be  $62.6 \pm 27.2$ ,  $80.7 \pm 45.1$ , and  $104.6 \pm 62.3$  nm, respectively. A comparison of the measured sizes using both TEM and DLS are given in Table 1.

**Table 1.** Comparison of average hydrodynamic diameters measured using DLS and average core diameters determined using TEM for MNP-O, MNP-96, MNP-124, and MNP-142 distributions.

Sample	DLS (nm)	TEM (nm)
MNP-O	$137.21 \pm 20.8$	$75.4 \pm 47.7$
MNP-96	$96.3 \pm 9.0$	$62.6 \pm 27.2$
MNP-124	$123.6 \pm 7.9$	$80.7 \pm 45.1$
MNP-142	$141.5 \pm 10.8$	$104.6 \pm 62.3$






**Figure 5.** (a) Size distributions obtained from the original nanoparticle suspension (MNP-O) at flow rates of 10 mL/min (MNP-96), 40 mL/min (MNP-124), and LO (MNP-142); (b) Representative TEM image at 12.5 K magnification of original nanoparticle suspension, MNP-O, before separation; (c–e) Representative TEM images of MNP-96, MNP-124, and MNP-142 particle samples, respectively, at 85 K magnification.

### 3.4. Size-Dependent Relaxometric Properties of MNP Suspensions

The transverse relaxation time ( $T_2$ ), which is the decay constant for the magnetization vector ( $M_t$ ) perpendicular to the applied magnetic field in MRI, was used to characterize the magnetic properties of fractionated particles obtained using the mFFF approach. Tested samples included the original unseparated suspension (MNP-O; hydrodynamic diameter  $137.2 \pm 20.8$  nm) and separated particles, designated MNP-95 and MNP-151, possessing average diameters of  $94.8 \pm 7.7$  and  $151.2 \pm 11.2$  nm, respectively. A series of dilutions were made of each sample and the relaxivities ( $R_2 = 1/T_2$ ) of each sample determined by fitting of MRI data to the equation:

$$M_t = M_0 e^{-t/T_2} \quad (8)$$

Preliminary data, shown in Figure 6, indicates that as the average hydrodynamic diameter of the MNPs increased, the transverse proton relaxation time also increased. Considering the inverse relaxation times at the highest concentration used, the  $R_2$  values increased from 11.2 to 51.05  $\text{s}^{-1}$  as the MNP size increased from 95 to 151 nm. This size-dependent behavior is similar to that previously reported for magnetic particles of hydrodynamic sizes less than 100 nm [34]. Additionally, it is interesting to note that the  $R_2$  values of the MNP-O samples, which contain particles of the same size as both MNP-95 and MNP-151, as well as sizes between the two distributions, were consistently between the  $R_2$  values of MNP-95 and MNP-151. For example, the  $R_2$  value for the MNP-O sample with an iron concentration of 0.009 mg/mL was determined to be 14.3  $\text{s}^{-1}$  compared to the values of MNP-95 and MNP-151 at the same concentration of 5.2 and 27.87  $\text{s}^{-1}$ , respectively.



**Figure 6.** Transverse relaxivity  $R_2$  values for the MNP-95, MNP-151, and MNP-O distributions with respect to iron concentration.  $R^2$  values determined using linear trend line.

## 4. Experimental Section

### 4.1. Materials

fluidMAG-D (starch-coated magnetite ( $\text{Fe}_3\text{O}_4$ )) iron oxide nanoparticles (75 mg/mL) were obtained from Chemicell<sup>®</sup> GmbH (Berlin, Germany). Succinimidyl polyethylene glycol (mPEG-NHS) of molecular weight 5 kDa was obtained from Nanocs (New York, NY, USA). Dimethyl sulfoxide ( $(\text{CH}_3)_2\text{SO}$ , 99.9%) was obtained from BDH Chemicals. Epichlorohydrin ( $\text{C}_3\text{H}_5\text{ClO}$ , 99%) was obtained from Alfa Aesar (Ward Hill, MA, USA). Sodium hydroxide ( $\text{NaOH}$ , 97%) was obtained from BDH chemicals. Ferrozine iron reagent, monohydrate was obtained from J.T. Baker (Center Valley, PA, USA). Neocuproine hydrochloride monohydrate ( $\text{C}_{14}\text{H}_{12}\text{N}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ , 99%) was obtained from Acros. Ammonium acetate, ACS ( $\text{CH}_3\text{COONH}_4$ , 97% min) was obtained from Alfa Aesar. L-ascorbic acid ( $\text{C}_6\text{H}_8\text{O}_6$ ) was obtained from BDH. Iron standard solution (1.00 mg/L as Fe) was obtained from HACH. Deionized water ( $\text{DI-H}_2\text{O}$ ) was obtained using an ELGA PURELAB Flex water purification system.

#### 4.2. Surface Modification of Iron Oxide Nanoparticles

The IO-MNPs were cross-linked, aminated, and PEGylated according to previously established methodology [35]. First, 2 mL of MNP suspension (42 mg/mL) was incubated with 2.6 mL 6 M NaOH for 15 min. Epichlorohydrin (1.3 mL) was then added and the mixture incubated for 24 h at 25 °C with shaking. After incubation, the solution was thoroughly dialyzed against DI-H<sub>2</sub>O using a 8–10 kDa MWCO Float-A-Lyzer<sup>®</sup> G2 dialysis device (Spectrum Laboratories, Inc., Rancho Dominguez, CA, USA). The purified product was then incubated with 2 mL of concentrated NH<sub>4</sub>OH (30% ammonia) for a period of 24 h at 25 °C with shaking. The aminated-MNP suspension was then sufficiently dialyzed against DI-H<sub>2</sub>O and the final product was concentrated using a Sphero<sup>™</sup> Fleximag Separator (Spherotech, Lake Forest, IL, USA).

The PEGylation of the MNPs was achieved by utilizing NHS chemistry. First, 15 mg of mPEG-NHS was dissolved in a mixture of 320 µL of DMSO, 320 µL of DI-H<sub>2</sub>O, and 320 µL of pH 8 phosphate buffer. 320 µL of aminated-MNP solution was then added and the mixture was incubated at 25 °C with shaking. At the completion of incubation, the solution was diluted to ~7 mL with DI-H<sub>2</sub>O, placed on the magnetic separator, and then subjected to several washes with fresh DI-H<sub>2</sub>O. After washing, the PEG-MNP solution was diluted to the final desired concentration.

#### 4.3. Characterization of MNPs

*Dynamic Light Scattering (DLS)*—Dynamic light scattering was used to measure the intensity-weighted size (hydrodynamic diameter) distribution of nanoparticles. Measurements were taken in triplicate using a ZetaSizer Nano ZS90 sizing instrument (Malvern, Worcestershire, UK).

*Transmission Electron Microscopy (TEM)*—A Zeiss EM 10 TEM operating at a voltage of 60 kV was used to determine size distributions of MNPs. TEM samples were prepared by placing a single drop of a MNP solution onto a carbon type B, 300 mesh grid. The grid was then placed in a petri dish and allowed to dry at ambient conditions. Size distributions were obtained using ImageJ software to size a sufficient number of MNPs from multiple TEM images taken of each sample.

*Iron Content Assay*—The iron content of MNP solutions was determined using a ferrozine assay. Briefly, a 200 µL dilution (typically 1:1000) of the MNP sample was obtained in combination with 1 M HCl. 230 µL of KMnO<sub>4</sub>/HCl was added to the sample and mixed via pipette. The KMnO<sub>4</sub>/HCl solution was made by mixing equal volumes of 4.5% w/v KMnO<sub>4</sub> with 1.4 M HCl. The mixture was then incubated for 2 h at 60 °C followed by a 10 min cooling period. The sample was then mixed and transferred to a well plate via two 180 µL aliquots. Thirty microliters of prepared ferrozine solution was then added to the samples, mixed, and incubated at ambient conditions for 30 min. The prepared ferrozine solution was composed of 6.5 mM ferrozine, 6.5 mM neocuprine, 2.5 M ammonium acetate, and 1 M ascorbic acid dissolved in DI-H<sub>2</sub>O. The absorbance of the samples at 550 nm was then measured using a SpectraMax i3 plate reader (Molecular Devices, Sunnyvale, CA, USA). Standard curves were created using an iron standard solution.

#### 4.4. Magnetic Separation Prototype Operation

The magnetic separation prototype was created using styrofoam to create a block for the five cylindrical magnets and a platform for the tubing. 1/16" I.D. silicone tubing (VWR) was used to replicate the 2D channel in the simulation. 100  $\mu\text{m}$  flexible fused silica capillary tubing (Molex, Lisle, IL, USA) was used to inject the nanoparticle solution into the mobile phase at the wall opposite the magnets. This tubing was connected to a 1 mL syringe fitted with a 30 G needle via a small section of 0.011" ID polyethylene tubing (Clay Adams, Sparks, MD, USA). The mobile phase was supplied by two syringe infusion pumps (KD Scientific, Holliston, MA, USA) in order to control the flow rate of the system.

For a typical run, the desired flow rate of the mobile phase was set to 0.036 mL/s using the syringe pumps and infusion was started. The concentrated nanoparticle suspension was then injected into the mobile phase by applying a small amount of pressure to the syringe plunger. The nanoparticle suspension was continually injected until the desired volume (approximately 0.1 mL) had been run through the magnetic separation prototype. After this, infusion of the mobile phase was terminated and the two obtained fractions were characterized. The whole system was flushed sufficiently with DI water to ensure no cross-contamination between runs.

#### 4.5. Field-Flow Fractionation Prototype Operation

For all field-flow fractionation experiments, the desired volume of concentrated nanoparticle suspension was injected into 1/8" ID silicone tubing (VWR, Radnor, PA, USA) in the absence of flow from the mobile phase. The nanoparticles were then allowed to collect at the wall of the tubing closest to the magnet for a period of 15 min to allow for a steady-state distribution of particles at the tubing wall. The mobile phase was then introduced at a low initial flow rate using a peristaltic pump (Thermo Fisher Scientific, Waltham, MA, USA) in order to wash away any MNPs that had not collected at the tubing wall. After the entire volume of the silicone tubing was washed, flow from the pump was stopped, the sample volume was removed from the collection vessel for characterization, and then the collection vessel was rinsed with DI water and placed at the outlet. A higher flow rate was then introduced into the system and another sample was collected. This process was repeated for all desired flow rates supplied by the pump. Lastly, MNPs remaining in the tubing were removed by flushing with DI water after removal of the magnetic field.

#### 4.6. Relaxometric Property Determination Using MRI

Relaxometry measurements were performed using a Siemens Verio Open-Bore 3T Scanner to determine the transverse proton relaxation times of solutions of iron oxide nanoparticles via spin-echo pulse sequences. For measurements of aqueous MNP solutions, samples were placed in either 0.6 or 1.6 mL plastic microfuge tubes and the tubes submerged in water spiked with copper sulfate ( $\text{CuSO}_4$ ) to control background noise. The relaxation times of each sample were determined by plotting the magnitude of the measured MR signal at each of the echo times used in the spin-echo sequence and using a curve-fitting MATLAB script.

## 5. Conclusions

For the full potential of magnetic nanoparticles in nanomedicine to be realized, methods must be developed that allow for the distinct control of their physical and chemical properties so that particles may be optimized for specific applications. One of the most important factors that determines the behavior of magnetic nanoparticles *in vivo* is their size; however, current synthesis methods do not allow for sufficient size control for iron oxide nanoparticles of diameters greater than 30 nm. While initial Matlab simulations indicated that size-selective separation could be achieved by using magnetic fields to isolate MNPs from a liquid flow field, subsequent experiments were unable to confirm the results predicted by the model. Since a ferrofluid-type behavior was observed, the discrepancy between the theoretical and experimental results could be due to the assumption that particle-particle interactions were not significant within the model. Further improvements to both the model and the experimental setup are ongoing to validate this approach for the size-selective separation of magnetic nanoparticles. Despite this initial failing, an approach utilizing mechanisms similar to magnetic field-flow fractionation was found to be an effective method for the separation of polydisperse suspensions of iron oxide nanoparticles with diameters greater than 20 nm. While similar methods have been previously used to separate magnetic nanoparticles, there has been very little reported on the separation of particles in the size range of 50–400 nm. TEM and DLS analysis of particles obtained using this approach confirmed that particles of varying size and lower polydispersity can indeed be obtained within this size range.

An advantage of the magnetic separation approach used here is its simplicity and use of basic laboratory equipment, not requiring, for example, the special membranes required for cross-flow FFF. With a simple neodymium magnet, tubing, and a source of variable flow, this approach is easily adoptable to other laboratories. Ongoing studies are further refining the separation efficiency and scaling-up the approach to generate higher concentration of particles required for *in vivo* studies. These studies and further optimization of the system presented in these investigations could allow for the production of very narrow size distributions of magnetic nanoparticles within the size range relevant for biomedical applications in a very simple and economic manner. This could substantially improve the potential for clinical translation of these particles by enabling the fundamental studies necessary to understand the disposition of these particles *in vivo*.

## Acknowledgments

Hunter B. Rogers is a recipient of a fellowship from the Alabama EPSCoR Graduate Research Scholars Program. This material is also partially supported by the National Science Foundation under Grant No. EPS-1158862 Subagreement 34-21530-200-76190, by a Department of Defense FY2012 Prostate Cancer Research Program (PCRP) Idea Development Award (Grant #PC120946), and by a grant from the Auburn University Research Initiative in Cancer (AURIC). Additionally, Tareq Anani has been partially supported by an AURIC Graduate Fellowship.

## Author Contributions

Hunter B. Rogers and Allan E. David conceived and designed the experiments; Hunter B. Rogers, Tareq Anani, Ronald J. Beyers and Young Suk Choi performed the experiments; Hunter B. Rogers, Ronald J. Beyers and Allan E. David analyzed the data; Hunter B. Rogers and Allan E. David wrote the paper.

## Conflicts of Interest

The authors declare no conflict of interest.

## References

1. Freitas, R.A., Jr. *Nanomedicine, Volume I: Basic Capabilities*; Landes Bioscience: Georgetown, TX, USA, 1999.
2. Kim, B.Y.S.; Rutka, J.T.; Chan, W.C.W. Nanomedicine. *N. Engl. J. Med.* **2010**, *363*, 2434–2443.
3. Cho, K.; Wang, X.; Nie, S.; Shin, D. Therapeutic nanoparticles for drug delivery in cancer. *Clin. Cancer Res.* **2008**, *14*, 1310–1316.
4. Lee, J.H.; Jun, Y.W.; Yeon, S.I.; Shin, J.S.; Cheon, J. Dual-mode nanoparticle probes for high-performance magnetic resonance and fluorescence imaging of neuroblastoma. *Angew. Chem.* **2006**, *118*, 8340–8342.
5. Doane, T.L.; Burda, C. The unique role of nanoparticles in nanomedicine: Imaging, drug delivery and therapy. *Chem. Soc. Rev.* **2012**, *41*, 2885–2911.
6. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Nanomedicine: Current status and future prospects. *FASEB J.* **2005**, *19*, 311–330.
7. Choi, H.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J.; Ipe, B.; Bawendi, M.; Frangioni, J. Renal clearance of quantum dots. *Nat. Biotechnol.* **2007**, *25*, 1165–1170.
8. Hillaireau, H.; Couvreur, P. Nanocarriers' entry into the cell: Relevance to drug delivery. *Cell. Mol. Life Sci.* **2009**, *66*, 2873–2896.
9. Moghimi, S.; Porter, C.; Muir, I.; Illum, L.; Davis, S. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating. *Biochem. Biophys. Res. Commun.* **1991**, *177*, 861–866.
10. Fang, C.; Shi, B.; Pei, Y.; Hong, M.; Wu, J.; Chen, H. *In vivo* tumor targeting of tumor necrosis factor- $\alpha$ -loaded stealth nanoparticles: Effect of MePEG molecular weight and particle size. *Eur. J. Pharm. Sci.* **2006**, *27*, 27–36.
11. Perrault, S.D.; Walkey, C.; Jennings, T.; Fischer, H.C.; Chan, W.C. Mediating Tumor Targeting Efficiency of Nanoparticles Through Design. *Nano Lett.* **2009**, *9*, 1909–1915.
12. Gao, J.; Gu, H.; Xu, B. Multifunctional magnetic nanoparticles: Design, synthesis, and biomedical applications. *Acc. Chem. Res.* **2009**, *42*, 1097–1107.
13. Thorek, D.L.; Chen, A.K.; Czupryna, J.; Tsourkas, A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. *Ann. Biomed. Eng.* **2006**, *34*, 23–38.

14. Laurent, S.; Forge, D.; Port, M.; Roch, A.; Robic, C.; Vander Elst, L.; Muller, R.N. Magnetic iron oxide nanoparticles: Synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. *Chem. Rev.* **2008**, *108*, 2064–2110.
15. Gupta, A.K.; Naregalkar, R.R.; Vaidya, V.D.; Gupta, M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. *Nanomedicine* **2007**, *2*, 23–39.
16. Josephson, L.; Rudin, M. Barriers to clinical translation with diagnostic drugs. *J. Nucl. Med.* **2013**, *54*, 329–332.
17. Lavik, E.; von Recum, H. The role of nanomaterials in translational medicine.pdf. *ACS Nano* **2011**, *5*, 3419–3424.
18. Wang, Y.X. Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. *Quant. Imaging Med. Surg.* **2011**, *1*, 35–40.
19. Hufschmid, R.; Arami, H.; Ferguson, R.; Gonzales, M.; Teeman, E.; Brush, L.; Browning, N.; Krishnan, K. Synthesis of phase-pure and monodisperse iron oxide nanoparticles by thermal decomposition. *Nanoscale* **2015**, *7*, 11142–11154.
20. Hyeon, T. Chemical synthesis of magnetic nanoparticles. *Chem. Commun.* **2003**, *8*, 927–934.
21. Park, J.; An, K.; Hwang, Y.; Park, J.-G.; Noh, H.-J.; Kim, J.-Y.; Park, J.-H.; Hwang, N.-M.; Hyeon, T. Ultra-large-scale syntheses of monodisperse nanocrystals. *Nat. Mater.* **2004**, *3*, 891–895.
22. Gu, L.; Fang, R.; Sailor, M.; Park, J. *In vivo* clearance and toxicity of monodisperse iron oxide nanocrystals. *ACS Nano* **2013**, *6*, 4947–4954.
23. Vickrey, T.M.; Garcia-Ramirez, J.A. Magnetic field-flow fractionation: Theoretical basis. *Sep. Sci. Technol.* **1980**, *15*, 1297–1304.
24. Bi, Y.; Pan, X.; Chen, L.; Wan, Q.-H. Field-flow fractionation of magnetic particles in a cyclic magnetic field. *J. Chromatogr. A* **2011**, *1218*, 3908–3914.
25. Carpino, F.; Moore, L.; Chalmers, J.; Zborowski, M.; Williams, P. Quadrupole magnetic field-flow fractionation for the analysis of magnetic nanoparticles. *J. Phys. Conf. Ser.* **2005**, *17*, 174–180.
26. Latham, A.H.; Freitas, R.S.; Schiffer, P.; Williams, M.E. Capillary magnetic field flow fractionation and analysis of magnetic nanoparticles. *Anal. Chem.* **2005**, *77*, 5055–5062.
27. Moeser, G.D.; Roach, K.A.; Green, W.H.; Alan Hatton, T.; Laibinis, P.E. High-gradient magnetic separation of coated magnetic nanoparticles. *AIChE J.* **2004**, *50*, 2835–2848.
28. Ditsch, A.; Lindenmann, S.; Laibinis, P.E.; Wang, D.I.; Hatton, T.A. High-gradient magnetic separation of magnetic nanoclusters. *Ind. Eng. Chem. Res.* **2005**, *44*, 6824–6836.
29. Beveridge, J.; Stephens, J.; Williams, M. Differential magnetic catch and release: Experimental parameters for controlled separation of magnetic nanoparticles. *Analyst* **2011**, *136*, 2564–2571.
30. Bird, R.; Stewart, W.; Lightfoot, E. *Transport Phenomena*; John Wiley & Sons: Hoboken, NJ, USA, 1960.
31. Shevkoplyas, S.S.; Siegel, A.C.; Westervelt, R.M.; Prentiss, M.G.; Whitesides, G.M. The force acting on a superparamagnetic bead due to an applied magnetic field. *Lab Chip* **2007**, *7*, 1294–1302.
32. Berg, H. *Random Walks in Biology*; Princeton University Press: Princeton, NJ, USA, 1993.
33. Kourki, H.; Famili, M.H.N. Particle sedimentation: Effect of polymer concentration on particle–particle interaction. *Powder Technol.* **2012**, *221*, 137–143.

34. Roca, A.G.; Veintemillas-Verdaguer, S.; Port, M.; Robic, C.; Serna, C.J.; Morales, M.P. Effect of nanoparticle and aggregate size on the relaxometric properties of MR contrast agents based on high quality magnetite nanoparticles. *J. Phys. Chem. B* **2009**, *113*, 7033–7039.
35. Cole, A.J.; David, A.E.; Wang, J.; Galbán, C.J.; Hill, H.L.; Yang, V.C. Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting. *Biomaterials* **2011**, *32*, 2183–2193.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>).